Name (Synonyms) | Correlation | |
---|---|---|
drug485 | MRx-4DP0004 Wiki | 0.71 |
drug536 | Nafamostat Mesilate Wiki | 0.71 |
drug616 | Placebo Wiki | 0.15 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.22 |
D018352 | Coronavirus Infections NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
This is a clinical trial in which healthy volunteers will be administered an experimental MERS vaccine. The vaccine ChAdOx1 MERS will be administered alone both as a single administration and with a homologous prime-booster.
Description: The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events. Change from baseline for safety laboratory measures will also be collected. Occurrence of serious adverse events will be collected during the whole study duration
Measure: Occurrence of solicited and unsolicited local and systemic adverse events Time: up to 28 days following vaccinationDescription: ELISA to quantify antibodies to MERS Spike protein antigen Ex vivo ELISpot responses to MERS Spike protein antigen
Measure: Measures of immunogenicity to the ChAdOx1 MERS vaccine Time: 12 monthsA phase Ib study to determine the safety and immunogenicity of the candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers
Description: The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events. Change from baseline for safety laboratory measures will also be collected. Occurrence of serious adverse events will be collected during the whole study duration
Measure: Occurrence of solicited and unsolicited local and systemic adverse events Time: 28 days following the vaccinationDescription: ELISA to quantify antibodies to MERS Spike protein antigen Ex vivo ELISpot responses to MERS Spike protein antigen
Measure: Measures of immunogenicity to the ChAdOx1 MERS vaccine Time: 6.5 months following completion of the vaccination regimen